Home › All Companies › TELA › Annual Report

TELA Bio, Inc. (TELA) — Annual Report

AI-Powered SEC Filing Analysis

← All TELA filings
Latest Annual Report Filed: 2026-03-25

Key Insights

  • TELA Bio reported full-year 2025 results, with revenue growth across its Ovitex, Ovitex PRS, and other customer product lines.
  • The company secured additional financing through a registered direct offering and the Perceptive credit facility, strengthening its balance sheet.
  • TELA Bio continues to invest in its product pipeline and manufacturing capabilities, positioning the company for future growth.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-25. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.